Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments

May 1, 2024

https://www.globenewswire.com/news-release/2024/05/01/2873316/0/en/Elevai-Labs-Acquires-Exclusive-License-to-Two-Myostatin-Muscle-Loss-Prevention-Assets-with-Plan-to-Develop-in-Combination-with-GLP-1-Obesity-Treatments.html

NEWPORT BEACH, Calif., May 01, 2024 (GLOBE NEWSWIRE) — ELEVAI LABS, INC. (NASDAQ:ELAB) (the “Company”), today announced that it has entered into an exclusive licensing agreement with MOA Life Plus Co., Ltd., (“MOA”) a South Korean corporation, with the aim to develop and commercialize two novel assets for the treatment of obesity and muscle loss prevention.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.